Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Show more
2916 North Miami Avenue, Miami, FL, 33127, United States
Start AI Chat
Market Cap
39.8M
52 Wk Range
$2.10 - $7.40
Previous Close
$2.48
Open
$2.45
Volume
53,530
Day Range
$2.45 - $2.70
Enterprise Value
19.14M
Cash
35.4M
Avg Qtr Burn
-6.169M
Insider Ownership
9.80%
Institutional Own.
24.27%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ENTADFI™ (tadalafil and finasteride) Details Benign prostatic hyperplasia (BPH) | Approved Update | |
Enobosarm +/- abemaciclib Details HER2-expressing cancers, ER+/HER2- breast cancer | Phase 3 Update | |
Phase 2b Update | ||
Enobosarm Details Obesity | Phase 2b Initiation | |
Sabizabulin Details Atherosclerotic cardiovascular disease | IND Submission | |
VERU-100 Details Prostate cancer, Cancer | Failed Discontinued | |
Zuclomiphene citrate Details Hot flashes | Failed Discontinued | |
Sabizabulin (Veru-111) Details COVID-19 | Failed Discontinued | |
Sabizabulin (VERU-111) Details Castration-resistant prostate cancer | Failed Discontinued | |
Sabizabulin (VERU-111) + Enobosarm Details Triple-negative breast cancer , Cancer | Failed Discontinued |
